Study cancelled before enrollment

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.

Inclusion criteria:

• Type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment
• Body mass index between 20 and 40
• Females of childbearing potential must use adequate birth control.

Exclusion criteria:

• Subjects with previous use of insulin
• Type 1 diabetes
• Uncontrolled thyroid disease
• History of drug or alcohol abuse in the past year
• Any other clinically significant disease.